NL-OMON34410已完成不适用
AN OPEN-LABEL, SINGLE CENTRE TRIAL TO INVESTIGATE THE MASS BALANCE AND METABOLITE PROFILE OF A SINGLE ORAL DOSE OF AIC090019 - AIC090019 mass balance/Met-ID trial
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Healthy male
- •- 18-45 years of age, inclusive
- •- BMI 18.0-28.0 kg/m2
- •- Non-smoker or light to moderate smoker
排除标准
- •Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor (50 mL or more) within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study. Participation is also not permitted when participated in more than 3 other drug studies in the 10 months prior to the start of this study.
研究者
相似试验
进行中（未招募）
1 期
Full title of the trial : A Single Centre, Open-Label, Bridging Study of the Safety, Pharmacokinetics and Efficacy of Recombinant Human Acid Alpha-Glucosidase (rhGAA) Treatment in Patients with Late-Onset Pompe Disease (Glycogen Storage Disease Type II) - mini LOTSGlycogen Storage Disease type II (Pompe´s disease)EUCTR2005-002829-31-BEGenzyme Europe BV5
进行中（未招募）
1 期
Full title of the trial : A Single Centre, Open-Label, Bridging Study of the Safety, Pharmacokinetics and Efficacy of Recombinant Human Acid Alpha-Glucosidase (rhGAA) Treatment in Patients with Late-Onset Pompe Disease (Glycogen Storage Disease Type II) - mini LOTSGlycogen Storage Disease type II (Pompe´s disease)EUCTR2005-002829-31-GBGenzyme Europe BV5
已完成
不适用
SINGLE-CENTER, OPEN-LABEL STUDY INVESTIGATING THE EXCRETION BALANCE, PHARMACOKINETICS AND METABOLISM OF A SINGLE ORAL DOSE OF [14C]-LABELED RO4917523 AND AN INTRAVENOUS TRACER DOSE OF [13C]-LABELED RO4917523 IN HEALTHY MALE VOLUNTEERSdepressive disorders10027946anxietyNL-OMON35686F Hoffmann-La Roche Ltd6
进行中（未招募）
1 期
Study to investigate safety and tolerability of intravenous lacosamide in children.MedDRA version: 20.0 Level: PT Classification code 10015037 Term: Epilepsy System Organ Class: 10029205 - Nervous system disordersEpilepsyEUCTR2014-003294-42-DECB BIOSCIENCES Inc.75
进行中（未招募）
1 期
Study to investigate safety and tolerability of intravenous lacosamide in children.MedDRA version: 20.0 Level: PT Classification code 10015037 Term: Epilepsy System Organ Class: 10029205 - Nervous system disordersEpilepsyEUCTR2014-003294-42-HUCB BIOSCIENCES Inc.100